169263 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing; Immunoassay; Biospecific binding assay; Materials therefor for cancer; Specifically defined cancers leukemia
GARP AS A BIOMARKER AND BIOTARGET IN T-CELL MALIGNANCIES
#2SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS
#3THERAPY ASSESSMENT FOR HEMATOPOIETIC CANCER
#4METHODS FOR DETECTING ACUTE MYELOID LEUKEMIA
#5ANTI-CD7 NANOBODY, AND DERIVATIVE THEREOF AND USE THEREOF IN TUMOR THERAPY
#6LEUKEMIA TREATMENT
#7CD123 AND CD200 AS MARKERS FOR THE DIAGNOSIS AND IMMUNE-ERADICATION OF LEUKEMIC STEM CELLS (LSCS)
#8T-CELL RECEPTOR CONSTANT REGION 1 ANTIBODY OR T-CELL RECEPTOR CONSTANT REGION 2 ANTIBODY
#9Methods for Manipulating Phagocytosis Mediated by CD47
#10ANTI-CLL-1 CHIMERIC ANTIGEN RECEPTORS, ENGINEERED CELLS AND RELATED METHODS
#11MICROENVIRONMENTAL DETERMINANTS OF CLONAL HEMATOPOIESIS EXPANSION RATE
#12NOVEL LILRB4 ANTIBODIES AND USES THEREOF
#13NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER
#14DEPLETING TUMOR-SPECIFIC TREGS
#15NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF
#16BCR-ABL VARIANTS
#17ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA AND USES THEREOF
#18MPL MUTATIONS IN JAK2 V617F NEGATIVE PATIENTS WITH MYELOPROLIFERATIVE DISEASE
#19SMALL MOLECULE INHIBITOR TARGETING A LEUKEMIC STEM CELL ASSOCIATED GENE FOR HIGH-RISK AML PATIENTS
#20METHODS FOR EVALUATION AND TREATMENT OF TYROSINE KINASE INHIBITOR (TKI)-RESISTANT ACUTE MYELOID LEUKEMIA
#21METHODS AND SYSTEMS FOR DETERMINING LEUKEMIA OR LYMPHOMA LEVELS USING LYMPHOID IMAGES
#22LEUKEMIA-RELATED MARKER AND USE THEREOF
#23COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
#24DEVICE AND METHOD FOR LOCALISING OR IDENTIFYING MALIGNANCIES
#25METHODS OF DETECTING AND TREATING IMMUNOTHERAPY-RESISTANT CANCER
#26Crenolanib for Treating FLT3 Mutated Proliferative Disorders
#27METHODS FOR DETECTING DYSFUNCTIONAL NK CELLS IN LEUKEMIA PATIENTS
#28METHODS RELATING TO TREATMENT OF ACUTE MYELOID LEUKEMIA
#29SEQUENTIAL TREATMENTS AND BIOMARKERS TO REVERSE RESISTANCE TO KINASE INHIBITORS
#30SPECIMEN MEASUREMENT SYSTEM AND SPECIMEN MEASUREMENT METHOD
#31CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA
#32METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES
#33ANTIGEN CD111 AS A NEW SPECIFIC DIAGNOSTIC AND THERAPEUTIC MARKER FOR POLYMORPHONUCLEAR MYELOID-DERIVED SUPPRESSOR CELLS (PMN-MDSCS)
#34BIOLOGIC FOR THE TREATMENT OF CANCER
#35METHODS FOR DIAGNOSING HEMATOLOGICAL CANCERS
#36SPECTROGRAPHIC DETECTION OF ACUTE LEUKEMIA
#37METHOD FOR DETERMINING MEDICINAL EFFECT OR SENSITIVITY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY
#38PREDICTING CANCER RELAPSE
#39DETECTION OF ACUTE MYELOID LEUKAEMIA
#40ANTI-CD38 SINGLE DOMAIN ANTIBODIES IN DISEASE MONITORING AND TREATMENT
#41METHODS OF DETECTING AND REDUCING CANCER CELL CENTRAL NERVOUS SYSTEM COLONIZATION
#42DIAGNOSIS AND TREATMENT OF MYELOID DISORDERS AND ACUTE LEUKEMIAS USING NOVEL TUMOR SPECIFIC ANTIGENS
#43CARBONIC ANHYDRASE 1 (CA1) INHIBITORS FOR THE TREATMENT OR PREVENTION OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES, AND AS BIOMARKER OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES
#44METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS
#45PROGNOSTIC BIOMARKERS FOR CANCER RELAPSE VACCINATION AND THE USE THEREOF
#46HEMATOPOIETIC CELL PHENOTYPING USING CIRCULATING CELL-FREE MARKERS
#47COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION
#48HIGH PARAMETER 20 COLOR PANEL FOR EFFECTIVE DETECTION OF ABERRANT CELLS IN ACUTE MYELOID LEUKEMIA
#49Materials and Methods for Monitoring Cancer by Administering an Anti-MCL1 Antibody
#50MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS
#51COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
#52USES OF LABELED HSP90 INHIBITORS
#53HIGH PARAMETER REAGENT PANEL AND REAGENT KIT FOR EFFECTIVE DETECTION OF ABERRANT CELLS IN ACUTE MYELOID LEUKEMIA
#54REAGENT COMPOSITION FOR IMMUNOPHENOTYPING OF B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA AND USE THEREOF
#55Antibody composition for immunotyping of myeloid tumor and use thereof
#56TEST METHOD, OF DIVIDING BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) INTO SUBTYPES
#57METHOD FOR SELECTING CANCER TREATMENT REGIMEN
#58METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA
#59AML ANTIGENS AND USES THEREOF
#60TRANSFER LEARNING ACROSS HEMATOLOGICAL MALIGNANCIES
#61Use of Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies
#62NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF
#63CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA
#64MONOLAYER OF PBMCS OR BONE-MARROW CELLS AND USES THEREOF
#65Detection reagent and therapeutic target for B cell tumor after targeted therapy and related application
#66METHODS FOR TREATING CANCER AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES
#67METHODS RELATED TO TOXICITY AND RESPONSE ASSOCIATED WITH CELL THERAPY FOR TREATING B CELL MALIGNANCIES
#68Method for Monitoring of Deep Remissions in Multiple Myeloma and Other Plasma Cell Dyscrasias
#69CHEMICAL COMPOSITIONS AND METHODS OF USE
#70USE OF CELL FREE NUCLEOSOMES AS BIOMARKERS
#71Crenolanib for treating FLT3 mutated proliferative disorders
#72TARGETING CIRCULAR PCMTD1 IN LEUKEMIAS WITH P53 MUTATIONS AND/OR BCR/ABL FUSIONS
#73SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS
#74METHOD OF DETECTING OR MONITORING MINIMAL RESIDUAL DISEASE IN A MONOCLONAL GAMMOPATHY PATIENT
#75CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
#76METHODS FOR TREATING LEUKEMIA AND USE OF A LEUKEMIC STEM CELL SIGNATURE TO PREDICT CLINICAL SENSITIVITY TO THERAPIES
#77Markers of acute myeloid leukemia stem cells
#78METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY
#79METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS
#80Methods of Enhancing Immunogenicity of Cancers
#81BIOMARKERS FOR NON-HODGKIN LYMPHOMAS AND USES THEREOF
#82Markers of acute myeloid leukemia stem cells
#83FLT3-specific chimeric antigen receptors and methods using same
#84MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES
#85MONOCLONAL ANTIBODIES AND METHODS OF USE
#86TARGETING GALECTIN-9 AS A THERAPEUTIC STRATEGY FOR T-CELL EXHAUSTION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
#87METHOD AND COMPOSITION FOR PREDICTING EFFICACY OF BCL2/BCL-XL INHIBITORS ON CANCER
#88SPECIMEN MEASUREMENT SYSTEM AND SPECIMEN MEASUREMENT METHOD
#89BCR-ABL variants
#90ANTI-AXL ANTIBODIES
#91METHODS FOR IDENTIFYING BIOMARKERS TO PREDICT TREATMENT RESPONSE
#92BIOMARKERS FOR SELINEXOR
#93ANTI-VISTA ANTIBODIES AND FRAGMENTS
#94ANTIBODIES THAT BIND TO CLEAVED FORM OF MUTANT CALRETICULIN, AND DIAGNOSTIC, PREVENTIVE, OR THERAPEUTIC AGENT FOR MYELOPROLIFERATIVE NEOPLASM
#95METHODS OF DETECTING AND REDUCING CANCER CELL CENTRAL NERVOUS SYSTEM COLONIZATION
#96COMPOSITIONS AND METHODS RELATED TO LATROPHILINS AS BIOMARKERS FOR HAEMATOPOIETIC CELL CANCER
#97Identification of a JAK2 Mutation in Polycythemia Vera
#98BINDING DOMAIN
#99METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA BY ERADICATING LEUKEMIC STEM CELLS
#100Markers of acute myeloid leukemia stem cells
#101METHODS FOR DETECTING ACUTE MYELOID LEUKEMIA
#102METHODS OF TREATING CANCER
#103METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#104LILRB4 antibodies and uses thereof
#105Depleting tumor-specific tregs
#106Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
#107T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody
#108TREATMENT OF T CELL LYMPHOMA
#109Methods for identifying LILRB-blocking antibodies
#110METHODS OF SELECTING TREATMENT FOR CXCR4-ASSOCIATED CANCER
#111Methods determining and treating cellular resistance to ADP-rtbosylating toxin
#112Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
#113METHODS FOR DIAGNOSING HEMATOLOGICAL CANCERS
#114METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS
#115Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
#116IDENTIFICATION OF IMMUNOGLOBULINS USING MASS SPECTROMETRY
#117Biomarkers for predicting responsiveness to decitabine therapy
#118PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
#119Methods for manipulating phagocytosis mediated by CD47
#120METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY
#121BIOMARKERS, USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION, AND IMMUNOTHERAPY METHODS
#122Methods, reagents and kits for detecting minimal residual disease
#123BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO CHIMERIC ANTIGEN RECEPTOR THERAPY AND USES THEREOF
#124CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
#125ANTIBODIES ANTI TUMOR ASSOCIATED ANTIGENS AND METHOD FOR OBTAINING THEM
#126COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
#127Uses of labeled HSP90 inhibitors
#128Synthesis and composition of non-amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
#129SH2 domain-based prognostic biomarker for chronic lymphocytic leukemia
#130Biologic for the treatment of cancer
#131PREDICTING RESPONSE TO ALVOCIDIB BY MITOCHONDRIAL PROFILING
#132Markers of acute myeloid leukemia stem cells
#133METHOD FOR DETECTING AN ANTIGEN-SPECIFIC ANTIBODY AND REAGENT FOR USE THEREIN
#134ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
#135MPL MUTATIONS IN JAK2 V617F NEGATIVE PATIENTS WITH MYELOPROLIFERATIVE DISEASE
#136NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER
#137INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF
#138Combined markers for metastatic cancer and uses thereof
#139Stratification of acute myeloid leukaemia patients for sensitivity to kinase pathway inhibitor therapy
#140Crenolanib for treating FLT3 mutated proliferative disorders
#141BCR-ABL variants
#142MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS
#143Polymer backbone element tags
#144Profiling and treatment of MYC-associated cancers with NK cells and type 1 interferon
#145Approach for universal monitoring of minimal residual disease in acute myeloid leukemia
#146Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
#147Anti-PD-L1 antibodies and methods of using the same for detection of PD-L1
#148MEASUREMENT SUCCESS/FAILURE DETERMINATION METHOD AND SAMPLE MEASUREMENT DEVICE
#149TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms
#150Prognostic marker for myeloproliferative neoplasms
#151Markers of acute myeloid leukemia stem cells
#152DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#153CANCER DIAGNOSIS USING KI-67
#154Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
#155USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA
#156Betaretrovirus epitopes and related methods of use
#157Inflammasome activation in myelodysplastic syndromes
#158Identification of a JAK2 mutation in polycythemia vera
#159Screening method for diagnosis of haematological neoplasia
#160Antibodies binding to soluble BCMA
#161Specimen measurement system and specimen measurement method
#162Dynamic BH3 profiling
#163SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#164SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#165METHODS APPARATUSES AND SYSTEMS FOR DETECTING AND QUANTIFYING PHOSPHOPROTEINS
#166Anti-LILRB antibodies and their use in detecting and treating cancer
#167METHODS FOR DETERMINING INTERACTION BETWEEN BIOLOGICAL CELLS
#168METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER
#169Treatment of acute myeloid leukemia
#170Mutant calreticulin for the diagnosis of myeloid malignancies
#171SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#172Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
#173NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF
#174Anti-vista antibodies and fragments
#175INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF
#176Compositions comprising glucosylated hydroxymethylated bases
#177Prognostic methods and systems of treatment for acute lymphoblastic leukemia
#178PREDICTING RESPONSE TO IMMUNOMODULATORY DRUGS (IMIDS) IN MULTIPLE MYELOMA PATIENTS
#179Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
#180COMPOSITIONS COMPRISING SOLUBLE CD84 OR ANTI-CD84 ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING B-CLL
#181Polymer backbone element tags
#182Methods for treating, diagnosing and prognosing a haematological malignancy
#183Identification of a JAK2 mutation in Polycythemia Vera
#184Method for identifying high-risk AML patients
#185Methods for identifying hydroxylated bases
#186METHODS OF DETERMINING DOSING OF A THERAPEUTIC AGENT BASED ON MEASURED LEVELS OF A METABOLITE
#187COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
#188Predicting response to alvocidib by mitochondrial profiling
#189DOT1L INHIBITION IN PATIENTS WITH MN1-HIGH AML
#190Anti-CLL-1 antibodies and immunoconjugates
#191A NOVEL INVADOPODIA-SPECIFIC MARKER OF INVASIVE CANCER STEM CELLS AND THE USE THEREOF
#192METHOD FOR THE PROGNOSIS OF MULTIPLE MYELOMA
#193Selective oxidation of 5-methylcytosine by TET-family proteins
#194FLT3-specific chimeric antigen receptors and methods using same
#195TIRC7 BASED DIAGNOSTIC AND THERAPY OF CANCER
#196COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, AND MONITORING OF IMMUNE DISORDERS USING GALECTIN-1
#197PHOSPHOLIPASE C GAMMA 2 AND RESISTANCE ASSOCIATED MUTATIONS
#198Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
#199METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS
#200Methods and compositions for identifying leukemic stem cells
#201Crenolanib for treating FLT3 mutated proliferative disorders
#202HDAC1,2 inhibitors and methods of using the same
#203METHOD FOR DETECTING AND ISOLATING INVASIVE CANCER STEM CELLS EMPLOYING CELL-SURFACE AMFR AND THE USE THEREOF
#204METHOD OF TREATING CHRONIC LYMPHATIC LEUKAEMIA AND/OR SYSTEMIC LUPUS ERYTHEMATOSUS
#205Biomarkers for non-hodgkin lymphomas and uses thereof
#206Monoclonal antibodies that specifically recognize canine DLA-DR antigen and their uses
#207Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
#208Use Of Wiskott-Aldrich Syndrome Protein (WASP) As A Biological Marker And In Vitro Method For Monitoring The Progression Of A Hematological Disease
#209COMPOSITIONS AND METHODS FOR THE DETECTION DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES
#210Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia
#211CELLULAR CIS-CO-CULTURE SYSTEMS AND METHODS
#212Mutant genes related to drug resistance and relapse of acute lymphoblastic leukaemia and a use thereof
#213DEPLETING TUMOR-SPECIFIC TREGS
#214TREATING PATIENTS BASED ON IMMUNE SUBTYPES
#215Polymer backbone element tags
#216Clinical assessment of M-protein response in multiple myeloma
#217COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
#218Induction of Regulatory B Cells for the Treatment of Immune Mediated Diseases
#219Hematopoietic cell phenotyping using circulating cell-free markers
#220Methods for distinguishing 5-hydroxymethylcytosine from 5-methylcytosine
#221SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#222SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#223Selective oxidation of 5-methylcytosine by TET-family proteins
#224Methods of treating acute myeloid leukemia
#225METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA
#226Predicting response to alvocidib by mitochondrial profiling
#227METHODS FOR DETECTION OF PLASMA CELL DYSCRASIA
#228Methods of detecting and reducing cancer cell central nervous system colonization
#229Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
#230Identification and use of new tumor-promoting gene in hematological malignancies
#231Anti-Axl antibodies
#232Anti CD84 antibodies, compositions comprising same and uses thereof
#233Methods for the identification, evaluation and treatment of patients having multiple myeloma
#234Method for determining presence or absence of suffering from malignant lymphoma or leukemia, and agent for treatment and/or prevention of leukemia
#235ANTIBODIES FOR TARGETING CANCER STEM CELLS AND TREATING AGGRESSIVE CANCERS
#236Hypomethylation of TET2 target genes for identifying a curable subgroup of acute myeloid leukemia
#237Methods and compositions relating to proteasome inhibitor resistance
#238Conjugates of RGD peptides and (bacterio)chlorophyll photosensitizers
#239Methods and materials for identifying therapeutic response in chronic myeloid leukemia
#240DETECTION OF ACUTE MYELOID LEUKAEMIA
#241BCR-ABL1 splice variants and uses thereof
#242Detection of 5-hydroxymethylcytosine by glycosylation
#243Method of treatment of leukemia with anti-IL1RAP antibodies
#244S100A9 levels for predicting lenalidomide and erythropoietin responsiveness
#245Labeling hydroxymethylated residues
#246KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS
#247INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF
#248USE OF BIOMARKERS FOR PREDICTING CLINICAL SENSITIVITY TO CANCER TREATMENT
#249Processes for the diagnosis, prognosis and monitoring of the progression of chronic lymphoid leukaemia (CLL) and/or of systemic lupus erythematosus (SLE) using membrane STIM 1
#250Method and kit for testing chronic myelogenous leukemia (CML), method for isolating TKI-resistant CML cells, and agent for reducing TKI-resistance of CML and method for screening the same
#251MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES
#252LYMPHOID HEMOPATHY PROGNOSIS METHOD
#253SURROGATE FUNCTIONAL DIAGNOSTICS TEST FOR CANCER
#254INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF
#255NEW BIOMARKER FOR OUTCOME IN AML PATIENTS
#256METHODS FOR TREATING HEMATOLOGICAL CANCER AND THE USE OF BIOMARKERS AS A PREDICTOR FOR RESPONSIVENESS TO TREATMENT COMPOUNDS
#257MODULATING URACIL-DNA GLYCOSYLASE AND USES THEREOF
#258METHODS FOR DETERMINING DRUG EFFICACY USING CEREBLON-ASSOCIATED PROTEINS
#259Cancer Diagnostic
#260Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
#261JAM-C antibodies and methods for treatment of cancer
#262AML antigens and uses thereof
#263POLYPEPTIDE SPECIFICALLY BINDING TO CD34 MOLECULE AND USE THEREOF
#264Inflammasome activation in myelodysplastic syndromes
#265Immune profiling and minimal residue disease following stem cell transplantation in multiple myeloma
#266DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-ITM2A ANTIBODY
#267DIAGNOSTIC TEST INVOLVING ANTI-CD25-ADC
#268Methods, reagents and kits for detecting minimal residual disease
#269Substituted purine compounds
#270Methods and compositions for identifying leukemic stem cells
#271Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof
#272Selective oxidation of 5-methylcytosine by TET-family proteins
#273Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index
#274NEW BIOMARKER FOR OUTCOME IN AML
#275Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof
#276Anti-LILRB antibodies and their use in detecting and treating cancer
#277COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
#278RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
#279Methods for diagnosing hematological cancers
#280Inflammasome activation in myelodysplastic syndromes
#281Anti-CLL-1 antibodies and immunoconjugates
#282Anti-CLL-1 antibodies and immunoconjugates
#283MPL mutations in JAK2 V617F negative patients with myeloproliferative disease
#284COMPOSITIONS AND METHODS FOR THE DETECTION DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES
#285Markers of acute myeloid leukemia stem cells
#286Crenolanib for treating FLT3 mutated proliferative disorders
#287Methods of selecting and isolating cancer stem cells
#288Anti-CLL-1 antibodies and immunoconjugates
#289BCR-ABL variants
#290Prognostic Marker For Cryoglobulinemic Vasculitis And B Cell Malignancies In HCV Infected Patients
#291Biomarkers for predicting responsiveness to decitabine therapy
#292METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT
#293Compositions and methods for treating multiple myeloma
#294Monolayer of PBMCs or bone-marrow cells and uses thereof
#295Monoclonal antibodies and methods of use
#296NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER
#297CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN BINDING DOMAINS TO THE T CELL RECEPTOR BETA CONSTANT REGION
#298ANTIBODIES TO NTB-A
#299Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression
#300Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand